报价延迟最少15分钟:2026/05/19 10:09 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.9876 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.15/0.36
|
|
企业价值
65.30M
|
| 资产负债 |
|
每股账面净值
2.23
|
| 现金流量 |
|
现金流量率
0.14
|
| 损益表 |
|
收益
86.55M
|
|
每股收益
24.95
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction andin vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia. |
